CONTACT INFORMATIONBIOGRAPHYCREDENTIALSAWARDSCLINICAL TRIALSPUBLICATIONSVIDEOSAndrew D. Goodman, M.D.Contact InformationPhone NumbersAppointment: (585) 275-7854Administrative: (585) 275-7854Office: (585) 275-7854Fax: (585) 275-9953A member of the University of Rochester Medical Faculty GroupgroupAn Accountable Health PartnerassignmentNot Accepting New PatientsLocationsUniversity of Rochester Medical CenterSchool of Medicine and Dentistry601 Elmwood Ave, Box 605Rochester, NY 14642Faculty AppointmentsProfessor - Department of Neurology , Neuroimmunology (SMD) Patient Care SettingNeurologyBiographyProfessional BackgroundAndrew D. Goodman, MD is Professor of Neurology, Chief of the Neuroimmunology Unit, and Director of the Multiple Sclerosis Center at the University of Rochester. Dr. Goodman is a graduate of Rutgers College and the University of Medicine and Dentistry of New Jersey; he did residency training in internal medicine and neurology at Mt. Sinai Medical Center in New York City. He completed a research fellowship in the Neuroimmunology Branch at the National Institutes of Health, Bethesda, Maryland. Numerous publications reflect his interests in clinical and experimental therapeutics research as well as the immunology and virology of multiple sclerosis. Dr. Goodman has been principal investigator and a member of national and international steering committees for numerous clinical trials of new therapies for multiple sclerosis. Dr. Goodman is a past Chair of the Multiple Sclerosis Section of the American Academy of Neurology. He has served the National Multiple Sclerosis Society as Deputy Medical Officer, Co-Chair of the Long-term Care Committee, member of the Client Education Committee, and member of the Executive Committee of the National Clinical Advisory Board.CredentialsEducation1979MD | University of Medicine and Dentistry of New JerseyPost-doctoral Training & Residency09/01/1983 - 06/30/1988Fellowship in Neurology at National Institute of Health09/01/1980 - 06/30/1983Residency in Neurology at Mount Sinai Medical Center09/01/1979 - 06/30/1980Residency in Medicine at Mount Sinai Medical CenterVIEW ALL expand_moreAwards2005Fellow, American Academy of Neurology2004Impact Presentation Award, Congress of the European Committee for Treatment and Research in Multiple SclerosisLocation: Vienna2003Senior Faculty AwardSponsor: University of Rochester Department of NeurologyLocation: Rochester, NY2001Inductee, Volunteer Hall of FameSponsor: US National Multiple Sclerosis SocietyLocation: New Orleans, LA1999 - 2000Chair, Multiple Sclerosis SectionSponsor: American Academy of Neurology1998 - PresentNamed in Best Doctors in America1998 - 1999Chair-elect, Multiple Sclerosis SectionSponsor: American Academy of Neurology1997University of Rochester Neurology Resident Faculty Teaching AwardLocation: Rochester, NY1996 - PresentNamed in Best Doctors in America: Northeast.1982 - 1983Chief Neurology ResidentLocation: Mount Sinai Medical Center1979Alpha Omega Alpha1974A.B. with Distinction in Biochemistry1973 - 1974Henry Rutgers ScholarVIEW ALL expand_moreClinical TrialsA Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisLead Researcher: Andrew D Goodman The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by sustained Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis [PPMS] and secondary progressive multiple sclerosis [SPMS]). View Study Details PublicationsJournal Articles3/12/2016Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, . "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial." Lancet.. 2016 Mar 12; 387(10023):1075-1084. Epub 2016 Jan 28. 12/1/2015Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ. "Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial." Clinical therapeutics.. 2015 Dec 1; 37(12):2780-7. Epub 2015 Nov 10. 9/2015Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR, . "Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials." Multiple sclerosis : clinical and laboratory research.. 2015 Sep 0; 21(10):1322-31. Epub 2015 Jan 12. VIEW ALL PUBLICATIONSVideosplay_circle_filledAndrew Goodman, M.D., Discusses New Drug for Multiple Sclerosisplay_circle_filledSECOND OPINION | Multiple Sclerosis | APT | Full Episodeplay_circle_filledSECOND OPINION | Multiple Sclerosis | APT | WebisodeClose WindowSchedule an appointment with Andrew D. Goodman, M.D.Please answer the following questions to help us find the right appointment for you.Important: If you believe that you have a medical or psychiatric emergency, please call 911 or go to the nearest hospital. This website is not intended for emergency care.Have you seen this provider in the last 2 years?YesNoExisting Patient Schedule or request a follow up appointment online through MyChart. If you do not have a MyChart account, please close this window and call the appointment phone number. Andrew D. Goodman, M.D. is currently scheduling for the following appointment type(s): Our policy does not permit patients to establish care with multiple providers within the same practice or specialty without prior approval. If you choose a new provider in the same office, we will cancel the appointment. Please contact the office directly with questions on this policy.